drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous CD19-directed CAR T-cell therapy (also known as relma-cel/JWCAR029) in which a patient’s T cells are genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells, leading to MHC-independent T-cell activation, proliferation, cytokine release, and cytotoxic killing of CD19+ malignant cells; expected on-target B-cell aplasia.
nci_thesaurus_concept_id
C155878
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds CD19 on B cells, driving MHC-independent T-cell activation, expansion, cytokine release, and cytotoxic killing of CD19-positive malignant cells, with expected on-target B-cell aplasia.
drug_name
Relmacabtagene autoleucel
nct_id_drug_ref
NCT06149169